Skip to main content
. 2010 Jun 8;89(11):1133–1140. doi: 10.1007/s00277-010-0992-3

Fig. 2.

Fig. 2

Progression-free survival of patients treated for their relapsed and/or refractory multiple myeloma with PLD + bortezomib is plotted based on the presence of either the C/C, C/T, or T/T SNP at C3435T in MDR1 using the Kaplan–Meier method